Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06060704 |
TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | Phase
Phase 2
|
Date Added 2023-09-29 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | Phase
Phase 1
|
Date Added 2023-10-03 |
Location
Michigan, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
capecitabine, Sacituzumab govetican |
Tags
MSS/ MMRp
|
| NCT ID NCT06066424 |
TitlePhase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Phase
Phase 1
|
Date Added 2023-10-04 |
Location
Texas, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06099821 |
TitleKN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | Phase
Phase 2
|
Date Added 2023-10-25 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
apatinib, KN046, Regorafenib |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06102902 |
TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC | Phase
Phase 1
|
Date Added 2023-10-26 |
Location
California, United States
Colorado, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BET Bromodomain Inhibitor ZEN-3694, encorafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05286814 |
TitleM9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma | Phase
Phase 2
|
Date Added 2022-03-18 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06120127 |
TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence | Phase
Phase 2
|
Date Added 2023-11-07 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy, PD-1 antibody |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06253520 |
TitleAutologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Phase
Phase 1
|
Date Added 2024-02-12 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06300463 |
TitlePlatform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Phase
Phase 2
|
Date Added 2024-03-08 |
Location
New York, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AGEN1423, Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06302062 |
TitlePhase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2024-03-08 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Cyclophosphamide, IL-2, Serplulimab Injection, Tumor Associated Lymph node T cell |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
